QP not present in Company: Prohibition of Supply
Recommendation
10/11 February 2026
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
A new Non-Compliance Report (NCR, Report No: 2017090955) was published on the EudraGMDP site. On 21 September 2017, the Danish Medicines Agency performed an inspection at EuroPharma.DK ApS in Denmark. EuroPharma.DK ApS performs parallel import, repacking and distribution of pharmaceutical products.
During that inspection, it was considered that the secondary packing operations at the site do not comply with Good Manufacturing Practice. This was also based on the following observations:
- QP not present in company for supervision and competent interaction with staff and management
- QA department understaffed
- Inadequate follow-up and implementation of CAPAs
- Insufficient handling of deviations and complaints
- Inadequate GDP implementation
As a consequence, the respective manufacturing authorisation was suspended and medicinal products must not be re-packed by EuroPharma DK or any of their contract manufacturers and must not be released and distributed. What's interesting is the fact that the GMP certificate which was withdrawn was just issued after an inspection on 8 March 2017.
Source: EudraGMDP Database (Report # 2017090955)
Related GMP News
04.02.2026When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
27.01.2026New Ph. Eur. Publication Schedule
21.01.2026EU Pharma Package: EMA with single Point of Information
14.01.2026European QP Association Developments September through December 2025
14.01.2026Could a change of ownership be relevant to GMP?
07.01.2026Is QP Certification required when Products do not enter EU Territory?